ACM
ESPR icon

Antonetti Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Antonetti Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,100
Closed -$25K – 412
2021
Q3 		$25K Buy
+2,100
New +$30.6K 0.02% 229

Other funds holding ESPR

Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Antonetti Capital Management's ESPR Position: Q4 2021 in Review

Antonetti Capital Management sold out of Esperion Therapeutics (ESPR) in Q4 2021, closing a stake of 2,100 shares — an estimated $25K sold.

Antonetti Capital Management first reported a position in ESPR in Q3 2021 and held it in 1 quarter. The position peaked at $25K in Q3 2021. 133 funds tracked by Wall St. Rank hold ESPR as of Q4 2021.

  • Antonetti Capital Management reported no remaining Esperion Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Antonetti Capital Management sold 2,100 Esperion Therapeutics shares in Q4 2021, an estimated $25K.
  • Antonetti Capital Management first reported a position in Esperion Therapeutics in Q3 2021 and held it in 1 quarter.
  • Antonetti Capital Management's Esperion Therapeutics position peaked at $25K in Q3 2021.
  • 133 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2021.

Based on Antonetti Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.